$NVCR will collaborate with $MRK on a Phase 2 pilot study evaluating the concomitant use of Tumor Treating Fields and Keytruda (pembrolizumab) in PD-L1-positive non-small cell lung cancer (NSCLC) patients in a first-line setting. #goodcall https://t.co/eXv4Ri203o